A vaccine in renal cell carcinoma: Are we nearing reality?

Expert Review of Anticancer Therapy

Volumn 12, Issue 12, 2012, Pages 1503-1505

  Bedke, Jens ^a   Gouttefangeas, Cécile ^a   Kruck, Stephan ^a   Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

IMA 901; immune therapy; renal cell carcinoma; tumor associated antigen; tyrosine kinase inhibitor; vaccination

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMA 901; INTERLEUKIN 2; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PEPTIDE VACCINE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LONG TERM SURVIVAL; LOW DRUG DOSE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; VON HIPPEL LINDAU GENE;

CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; KIDNEY NEOPLASMS;

EID: 84871504824     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.139     Document Type: Review

References (16)

1. Ljungberg B, Campbell SC, Choi HY et al. The epidemiology of renal cell carcinoma. Eur. Urol. 60(4), 615-621 (2011
2. Ljungberg B, Cowan NC, Hanbury DC et al.; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: The 2010 update. Eur. Urol. 58(3), 398-406 (2010
3. Wright JC. Update in cancer chemotherapy: Genitourinary tract cancer, Part 1. J. Natl Med. Assoc. 79(12), 1249-1258 (1987
4. Kruck S, Bedke J, Kuczyk MA, Merseburger AS. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev. Anticancer Ther. 12(6), 777-785 (2012
5. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003
6. Ahmadzadeh M, Rosenberg SA IL-2 administration increases CD4+ CD25(hi Foxp3+ regulatory T cells in cancer patients. Blood 107(6), 2409-2414 (2006
7. Brookman-May S, Burger M, Wieland WF, Rössler W, May M, Denzinger S. Vaccination therapy in renal cell carcinoma: Current position and future options in metastatic and localized disease. Expert Rev. Vaccines 10(6), 837-852 (2011
8. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. doi:10.1038/ nm.2883 (2012) (Epub ahead of print
9. Hoos A, Eggermont AM, Janetzki S et al. Improved end points for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388-1397 (2010
10. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012
11. Seremet T, Brasseur F, Coulie PG. Tumorspecific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J. 17(5), 325-330 (2011
12. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
13. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008
14. Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111(12), 5610-5620 (2008
15. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15(6), 2148-2157 (2009
16. Bedke J, Laske K, Feyerabend S et al. Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur. Urol. Suppl. 11, e76 (2012)